CBIO
Crescent Biopharma
CBIO
CBIO
84 hedge funds and large institutions have $707M invested in Crescent Biopharma in 2018 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 33 increasing their positions, 16 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
5% more funds holding
Funds holding: 80 → 84 (+4)
0.13% more ownership
Funds ownership: 0.93% → 1.06% (+0.13%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
84
Holding in Top 10
1
Calls
$6.31M
Puts
$2.06M
Top Buyers
| 1 | +$40.7M | |
| 2 | +$35.9M | |
| 3 | +$26.9M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$12.2M |
Top Sellers
| 1 | -$8.35M | |
| 2 | -$8.07M | |
| 3 | -$4.82M | |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.42M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.99M |